Press Room

Panaxia Global Reports: Panaxia Israel Continues to Grow

  • 30 August 2020

Panaxia’s agreement with international pharma Neuraxpharm is finalized

  • 17 July 2020

Panaxia Global Reports Record Revenues of its Israeli operations: The preliminary outlook projects at least 14 million in Q2 2020. Completes 11 consecutive quarters of growing revenues

  • 8 July 2020

Blazing The Trail To European Exports: Panaxia Israel Announces receipt of EU-GMP Certification, Required For The Manufacture And European Export Of Medical Cannabis And Advanced Products

  • 10 June 2020

Panaxia Global Reports Record Revenues for its Israeli activity In the First Quarter Of 2020

  • 8 June 2020

A breakthrough in the global medical cannabis market: Neuraxpharm enters the medical cannabis market as the first-ever European pharmaceutical company to market medical cannabis products

  • 1 April 2020

Panaxia is preparing for European sales: Announces an agreement for temporary use rights in an R&D facility in Malta for the commercial production and marketing of its European cannabis products in Europe

  • 30 March 2020

Panaxia Israel Announces successful completion of the capital raising of 23 million ILS in privately allocated by Israeli institution investors and the company’s controlling shareholders.

  • 26 March 2020

Hemp-based products of Panaxia US and partner Ultra Health receive distribution and manufacturing license: Having passed the New Mexico NMED audit, Panaxia US received a first-of-its-kind license to manufacture and distribute products throughout the US

  • 26 March 2020

A first-of-its-kind permit to export cannabis oil from the US to Israel was granted to Panaxia (TASE:PNAX) and its partner Ultra Health

  • 20 March 2020

First distribution agreement for Israeli medical cannabis products in Danish market: Panaxia Israel will distribute and sell medical cannabis oil through STENOCARE, the largest distributor of medical cannabis stock in Denmark

  • 12 March 2020

Excellent clinical trial results for leading Panaxia products: Results prove efficacy of absorption in the blood and safety of tablets, suppositories and inhaled cannabis extract

  • 10 December 2019

Joining forces with Prof. Aaron Ciechanover: Prof. Markus Veit, member of the German Pharmacopoeia and a world-renowned expert in the registration of herbal medicinal drugs, has joined the advisory committee to Panaxia’s board

  • 19 November 2019

Panaxia joins the front line of the largest companies in the world: The first and only company in Israel to successfully complete a European regulation audit towards receiving a European EU-GMP manufacturing standard which enables export of pharmaceutical cannabis products to Europe

  • 30 October 2019

Professor Aaron Ciechanover, Nobel Laureate in Chemistry, was appointed senior member in the advisory committee of Panaxia directorate

  • 20 September 2019

The merger deal of Panaxia Israel and Public company Herodium reaches the finish line

  • 18 September 2019

Panaxia Israel publishes its financial results for the first-half of 2019

  • 8 September 2019

A senior investment banker at Wall Street joins Panaxia: Orit Freedman Weissman, former partner at Goldman Sachs New-York, has been appointed Director in Panaxia

  • 28 May 2019

Panaxia Israel signed a Letter of Intent with Cannbit for the development of cannabis-based prescription drugs to relieve symptoms of ADHD and Fibromyalgia

  • 14 May 2019

Panaxia and Rafa sign a collaboration agreement with PlantEXT to research and manufacture the first medical cannabis suppositories intended for patients suffering from inflammatory bowel disease (IBD, Crohn's and colitis)

  • 1 May 2019

Revolutionizing Breakthrough for those suffering from chronic pain: a clinical research with medical cannabis sublingual tablets is currently on its way

  • 23 April 2019

Jonathan Kolber appointed Chairman of Panaxia Israel; Will also join as a shareholder in Panaxia Global with a 4-million-dollar investment

  • 24 March 2019

Good news for cancer patients treated with medical cannabis and suffering from breakthrough cancer pain: Panaxia has ended "In Human" phase in its clinical trial for one-of-a-kind metered-dose cannabis inhaler

  • 26 February 2019

Professor Aaron Ciechanover, Nobel Laureate in Chemistry, was appointed senior member in the advisory committee of Panaxia directorate

  • 14 February 2019